Clinical trials: Dendritic Cell
Glioblastoma, Vaccination
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Single arm, monocentric trial to assess the safety and the progression-free survival related to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate and temozolomide in patients operated for…
- Trial name
- Combi G-Vax (NCT04523688)
- Testing
- Autologous Dendritic Cells (DC) vaccine, Temozolomide
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
RATIONALE: Biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00937183
- Testing
- autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine, autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine, autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
- Where
- Poland
- Volunteers
- 12 people
- Sponsor
- Jan Walewski
Glioblastoma
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
This is a multicenter, open-label, randomized Phase II clinical study designed to evaluate the efficacy and safety of a personalized dendritic cell (DC) vaccine, ZSNeo-DC1.1, in combination with temozolomide (TMZ) as adjuvant…
- Trial name
- NCT07365280
- Testing
- Personalized Dendritic Cell Vaccine ZSNeo-DC1.1, Temozolomide (TMZ)
- Volunteers
- 78 people
- Sponsor
- ZSky Biotech Inc
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Registry-study of ELZONRIS in Participants With BPDCN
The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
- Trial name
- NCT07785154
- Testing
- Tagraxofusp
- Where
- 41 sites in Austria, Germany and 2 more
- Volunteers
- 80 people
- Sponsor
- Stemline Therapeutics, Inc.
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
- Trial name
- NCT00683670
- Testing
- cyclophosphamide, Mature dendritic cell vaccine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Pennsylvania
Diffuse Intrinsic Pontine Glioma
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
The purpose of this study is to asses safety of diffuse intrinsic pontine glioma (DIPG) treatment with autologous dendritic cells pulsed with lysated allegenic tumor lines Evaluate the nonspecific immune response generated in…
- Trial name
- NCT02840123
- Testing
- Autologous dendritic cells
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundació Sant Joan de Déu
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill prostate tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have…
- Trial name
- NCT00010127
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Lung Cancer
Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a gene-modified virus may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00049218
- Testing
- Autologous dendritic cell-adenovirus p53 vaccine, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT05857969
- Testing
- Functional Precision Medicine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Florida International University
Non Small Cell Lung Cancer
Dendritic Cells in Lung Cancer
Vaccination with autologous dendritic cells pulsed with allogeneic melanoma cell lysate (MelCancerVac) in combination with the Cox-2 inhibitor of celecoxib for the treatment of patients with advanced or metastatic non-small cell…
- Trial name
- NCT00442754
- Testing
- Allogeneic Tumour Lysate (MelCancerVac)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Herlev Hospital
Eye Diseases
Testing of Innocuousness of Benzalkonium Chloride on the Eye Concerning Possible Growth of Langerhans Cells
The study analysis the influence of benzalkonium chloride on the density of antigen presenting Langerhans cells. This is achieved in a double blind randomized study using in-vivo confocal microscopy to identify and quantify…
- Trial name
- NCT00414739
- Testing
- Benzalkonium chloride
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Rostock
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic
Glioblastoma, Astrocytoma, Grade IV
DC Migration Study for Newly-Diagnosed GBM
This randomized phase II study will assess the impact of pre-conditioning on migration and survival among newly diagnosed glioblastoma (GBM) patients who have undergone definitive resection and completed standard temozolomide…
- Conditions
- Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme
- Trial name
- ELEVATE (NCT02366728)
- Testing
- Unpulsed DCs, Td, Human CMV pp65-LAMP mRNA-pulsed autologous DCs
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Malignant Gliomas
Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy
Malignant gliomas are aggressive tumours with poor prognosis despite the current multimodal treatment. Hence, there is a clear need for new, effective therapies, among which immune therapy has emerged as a promising treatment…
- Trial name
- NCT01657734
- Testing
- MR imaging
- Where
- 2 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Melanoma
A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma
This phase I study plan is divided in the following four phases: Eligibility Screen Phase (week -4 to -1): Following written informed consent patients with metastatic melanoma (AJCC stage III/IV with unresectable disease) will…
- Trial name
- NCT01066390
- Testing
- TriMix-DC
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Bart Neyns
Malignant Pleural Mesothelioma
Autologous Dendritic Cell Vaccination in Mesothelioma
In this multicenter phase I/II trial, dendritic cells (DCs) loaded with the mesothelioma-associated tumor antigen WT1 will be used in conjunction with conventional chemotherapy for the frontline treatment of malignant pleural…
- Trial name
- MESODEC (NCT02649829)
- Testing
- dendritic cell vaccination plus chemotherapy
- Where
- 3 sites in Belgium
- Volunteers
- 28 people
- Sponsor
- University Hospital, Antwerp
Chronic Myeloproliferative Disorders, Leukemia
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
RATIONALE: A Web site for stem cell transplant health information and support may be effective in helping parents improve their health-related knowledge, skills, and quality of life, which may also improve their children's…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00782145
- Testing
- educational intervention, informational intervention, internet-based intervention
- Where
- 6 sites in United States
- Volunteers
- 198 people
- Sponsor
- Tufts Medical Center
Urothelial Carcinoma
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
- Trial name
- NCT01353222
- Testing
- DN24-02, Standard of Care
- Where
- 60 sites in United States
- Volunteers
- 142 people
- Sponsor
- Dendreon
Childhood Solid Tumor
Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood
This is an un-blinded Phase 1 study in which 21 patients suffering from solid advanced paediatric malignancies (14 sarcoma and 7 non-sarcoma patients) are treated with AV0113, an anti-tumour immune therapy with autologous…
- Trial name
- NCT02533895
- Testing
- AV0113 DC-CIT, Data evaluation
- Where
- 2 sites in Austria
- Volunteers
- 67 people
- Sponsor
- Activartis Biotech